Nuformix PLC

Nuformix plc is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing. The company specializes in discovering and developing novel drug forms with improved physical properties, particularly its lead program NXP002, which is an inhaled treatment for progressive fibrosing interstitial lung diseases, including Idiopathic Pulmonary Fibrosis. Nuformix operates primarily in the preclinical stage, targeting markets in the United States and Europe, and aims to secure licensing or collaborative agreements to advance its product pipeline.

Nuformix plc is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing. The company specializes in discovering and developing novel drug forms with improved physical properties, particularly its lead program NXP002, which is an inhaled treatment for progressive fibrosing interstitial lung diseases, including Idiopathic Pulmonary Fibrosis. Nuformix operates primarily in the preclinical stage, targeting markets in the United States and Europe, and aims to secure licensing or collaborative agreements to advance its product pipeline.